
The global DNA methylation market size reached USD 1.8 billion in 2024, grew to USD 2.05 billion in 2025, and is projected to hit around USD 6.45 billion by 2034, expanding at a CAGR of 13.64% during the forecast period from 2025 to 2034.
The R&D process for DNA methylation includes key aspects such as defining a research hypothesis, selection of a methylation detection method, sample collection, sample preparation, execution of the methylation detection method, and several other key considerations.
Key Players: Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., New England Biolabs, Agilent Technologies Inc.
Hospitals and pharmacies contribute to the acceptance of specialized kits, reagents, instruments, software, etc., from the distribution channels and the leading companies like Zymo Research, Thermo Fisher Scientific Inc., Illumina Inc., and QIAGEN.
Key Players: Exact Sciences, Agilent Technologies, Bio-Rad Laboratories, New England Biolabs.
DNA methylation plays a key role in early diagnosis of health conditions, risk assessment, guiding personalized treatments, disease monitoring, patient education, and counseling.
Key Players: Freenome, Inherent Biosciences, Inc., Nucleix Ltd., GRAIL, DNA Labs India.
In January 2024, Dominic John, Vice President, QIAGEN Digital Insights, proclaimed that the launch of Ingenuity Pathway Analysis (IPA) stands as a breakthrough in molecular data analysis, which combines human expertise and AI technology.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com